Wy‐46,300 and Wy‐46,531: Vascular Smooth Muscle Relaxant/Antihypertensive Agents with Combined Ca2+ Antagonist/Myosin Phosphorylation Inhibitory Mechanisms

@article{Silver1986Wy46300AW,
  title={Wy‐46,300 and Wy‐46,531: Vascular Smooth Muscle Relaxant/Antihypertensive Agents with Combined Ca2+ Antagonist/Myosin Phosphorylation Inhibitory Mechanisms},
  author={P. J. Silver and T. Sulkowski and R. Lappe and R. Wendt},
  journal={Journal of Cardiovascular Pharmacology},
  year={1986},
  volume={8},
  pages={1168–1175}
}
  • P. J. Silver, T. Sulkowski, +1 author R. Wendt
  • Published 1986
  • Chemistry, Medicine
  • Journal of Cardiovascular Pharmacology
  • 1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(pentafluorophenyl) −1,7 - naphthyridine - 3 - carboxylic acid methyl ester hydrochlorides with either a 3-phenoxy-2-hydroxypropyl (Wy-46,300) or 2-hydroxy-4-phenylbutyl (Wy-46,531) substituent at the 7 position are structurally novel vascular relaxant compounds which lower blood pressure by ∼35 mm Hg at 25 mg/kg p.o. in spontaneously hypertensive rats (SHR) or perinephritic hypertensive beagles. In contrast to standard Ca2+ blockers, both agents also… CONTINUE READING
    3 Citations
    Calcium-regulated protein kinases and low Km cGMP phosphodiesterases: targets for novel antihypertensive therapy.
    • 2
    Calcium channel antagonists part V: Second-generation agents
    • L. Opie
    • Medicine
    • Cardiovascular Drugs and Therapy
    • 2004
    • 3
    Second-Generation Agents
    • 3